Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
Background: Pooled analysis of phase 3, double-blind, doubledummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. Methods: Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoprox...
Saved in:
Main Authors: | Cohen C., Molina J., Cahn P., Clotet B., Fourie J., Grinsztejn B., Wu H., Johnson M., Saag M., Supparatpinyo K., Crauwels H., Lefebvre E., Rimsky L., Vanveggel S., Williams P., Boven K. |
---|---|
格式: | 雜誌 |
出版: |
2017
|
在線閱讀: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84862777419&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/42848 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
相似書籍
-
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials
由: Calvin J. Cohen, et al.
出版: (2018) -
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
由: Molina J., et al.
出版: (2017) -
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial
由: Jean Michel Molina, et al.
出版: (2018) -
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)
由: David A. Wohl, et al.
出版: (2018) -
Rilpivirine resistance- Associated mutations among antiretroviral- Naive patients infected with HIV-1 in Asia
由: Somnuek Sungkanuparph, et al.
出版: (2018)